Pharm-eco Laboratories, Inc.

Inotek Pharmaceuticals Corporation

Surface Logix, Inc.

Other

Agennix USA Inc.

The United States of America As Represented by the Department of Health

Gpc Biotech, Inc.

Gpc Biotech Ag

Siya Ram

Yesh P Sachdeva

Richard L Gabriel

Garry Southan

Salah A Zahr

Emile Al-Farhan

Biman Pal

Jaechul Shim

Arthur F Kluge

Zhongguo Wang

Alessandra Bartolozzi

Andrew L Salzman

Csaba Szabo

Paul Sweetnam

Krishna K Murthi

Stewart Campbell

Hope Foudoulakis

Brian Kirk

Chris Oalmann

Nicholas Bockovich

Bing Cai

John Henry Van Duzer

Dennis D Keith

Milton L Hammond

Sherman Tim Waddell

Alex Nivorozhkin

John F Finn

Milana M Maletic

Michael Morytko

Jianxing Huang

Gina M Santorelli

Aaron H Leeman

Hemalatha Seshadri

Qi Zeng

Prakash Jagtap

Xiaoyong Sun

Donna Kaye Wilson

Jon H Come

Frank Becker

Ravi Varma

The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.

Pharmacokinetically improved compounds

Rho-kinase inhibitors and method of preparation

The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, untimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.

Inhibitors of cyclin-dependent kinases, compositions and uses related thereto

The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.

The present invention relates to 5-Aryltetrazole Compounds, compositions comprising an effective amount of a a 5-Aryltetrazole Compound, and methods for treating an inflammation disease, a reperfusion disease, or hyperuricemia in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.

5-Aryltetrazole compounds and uses thereof

The present invention relates to 5-Aryltetrazole Compounds, compositions comprising an effective amount of a 5-Aryltetrazole Compound, and methods for treating an inflammation disease, a reperfusion disease, or hyperuricemia in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.

Aryltetrazole compounds, and compositions thereof

The present invention relates to 5-Aryltetrazole compounds, compositions comprising a 5-Aryltetrazole compound, and methods for treating an inflammation disease, a reperfusion disease, hyperuricemia, gout, or tumor-lysis syndrome in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.

5-Aryltetrazole compounds, compositions thereof, and uses therefor

The invention provides a novel class of substituted nucleoside derivatives having the formula:A-Z1-L-Z2-Gwherein: Pharmaceutical compositions, and methods of making and using the compounds, or pharmaceutically acceptable salts, hydrates, or mixtures thereof are also described.

Nucleoside compounds and compositions thereof

Prolines as antimicrobial agents

7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof

Growing community of inventors

Winchester, MA, United States of America

Siya Ram